Cabot-wellington Exits Position in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Cabot-wellington has sold out all of its stake in Abbott Laboratories during the most recent quarter, according to the disclosure filed by the company on Aug 9, 2016 with the SEC. The investment management company has sold out 165,135 shares of Abbott Laboratories which is valued at $7,439,332.

Other Hedge Funds, Including , At Bancorp boosted its stake in ABT in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 30,862 shares of Abbott Laboratories which is valued at $1,390,333. Abbott Laboratories makes up approx 0.20% of At Bancorp’s portfolio.Cobblestone Capital Advisors Ny reduced its stake in ABT by selling 1,051 shares or 5.5% in the most recent quarter. The Hedge Fund company now holds 18,070 shares of ABT which is valued at $817,848. Abbott Laboratories makes up approx 0.11% of Cobblestone Capital Advisors Ny’s portfolio. Quantitative Systematic Strategies added ABT to its portfolio by purchasing 9,417 company shares during the most recent quarter which is valued at $421,411. Abbott Laboratories makes up approx 0.18% of Quantitative Systematic Strategies’s portfolio.Foothills Asset Management Ltd. boosted its stake in ABT in the latest quarter, The investment management firm added 135 additional shares and now holds a total of 28,899 shares of Abbott Laboratories which is valued at $1,212,891. Abbott Laboratories makes up approx 0.94% of Foothills Asset Management Ltd.’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $44.68 with 86,30,316 shares getting traded on Wednesday. Post opening the session at $45.14, the shares hit an intraday low of $44.44 and an intraday high of $45.14 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.